Other
Functional Outcomes
0
Pipeline Programs↗
3
Active Trials↗
2
Companies Involved↗
Functional Outcomes is an early-stage landscape with 0 programs across 2 companies. The most active players are Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Eli Lilly.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
7
clinical trials
Completed3 · 43%
Recruiting3 · 43%
Terminated1 · 14%
Clinical Trials
Trial Activity
7 trials
Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
Recruiting·—·Phase 3·NCT04833426·140 enrolled
Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy
Completed·—·N/A·NCT02924922·85 enrolled
Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa
Terminated·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210626·192 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210626·192 enrolledData sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)